Luye Group 
Welcome,         Profile    Billing    Logout  
 36 Products   29 Diseases   36 Products   123 Trials   3033 News 


«12...678910111213141516...3334»
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  EMERGE 402: To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) -  Jun 30, 2022   
    P=N/A,  N=300, Recruiting, 
    Lurbinectedin could represent a valuable addition to therapies for ES, and is currently being evaluated in combination with irinotecan in advanced ES in a phase Ib/II trial. Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment open, Real-world evidence, Real-world effectiveness, Real-world:  LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) -  Jun 30, 2022   
    P=N/A,  N=200, Recruiting, 
    Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Pozenveo (poziotinib) / Assertio
    Trial primary completion date, EGFR exon 20, HER2 exon 20, Metastases:  NCI-2017-00831: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (clinicaltrials.gov) -  Jun 27, 2022   
    P2,  N=80, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Mar 2022 --> Mar 2023
  • ||||||||||  Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1109;    
    In our stage IV NSCLC population, there was no significant safety signal with sequential treatment of ICI followed by TKI; only one patient required treatment break/discontinuation due to pneumonitis. This differs from existing literature possibly because the majority of our population did not harbour a driver mutation and there were limited patients treated with crizotinib, ceritinib and osimertinib, other agents that have been associated with this safety signal.
  • ||||||||||  Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_978;    
    P2, P2/3
    With the increasing number of targeted therapies developed for molecularly-driven NSCLC, genomic profiling of all patients with advanced adenocarcinoma is crucial. When there is not enough tissue for molecular testing, plasma-based NGS can guide first-line treatment decisions in metastatic NSCLC and increase access to targeted therapy, which may lead to prolonged survival.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz, Tecentriq (atezolizumab) / Roche
    Tincture of Time (Main Room) -  May 25, 2022 - Abstract #Macula2022Macula_17;    
    The offending drug was atezolizumab (Tecentriq), a humanized IgG1 monoclonal antibody targeted against programmed cell death ligand 1 (PD-L1)...From a systemic standpoint, her metastatic CCS has continued to respond to combination treatment on clinical trial with lurbinectedin/irinotecan...This case underscores the importance of recognizing the full spectrum of checkpoint inhibitor-associated ocular ir-AEs. Objective: To describe the long-term clinical findings and visual prognosis in a rare form of checkpoint inhibitor-associated retinopathy.
  • ||||||||||  Journal:  The 2021 Marine Pharmacology and Pharmaceuticals Pipeline. (Pubmed Central) -  May 14, 2022   
    In 2021, new marine-derived drugs were approved by FDA, as well as in Australia and China. The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations (clinicaltrials.gov) -  May 12, 2022   
    P2,  N=19, Not yet recruiting, 
    The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I. Trial completion date: Mar 2026 --> Aug 2026 | Initiation date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2025 --> Aug 2025
  • ||||||||||  Lipusu (liposomal paclitaxel) / Luye Group
    Journal:  Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy. (Pubmed Central) -  May 10, 2022   
    Furthermore, stronger tumor growth inhibition was observed in LPC-Lip treated 4T1 tumor-bearing mice without significant side effects. In conclusion, by modulating the lipid composition of Lip, the antitumor efficacy can be improved, and LPC engineered Lip may serve as a promising formulation of PTX for future cancer therapy.